Technology evaluation: TransMID, KS Biomedix/Nycomed/Sosei/PharmaEngine
Rainov, N.G.; Söling, A.
Current Opinion in Molecular Therapeutics 7(5): 483-492
2005
ISSN/ISBN: 1464-8431 PMID: 16248284 Document Number: 592700
KS Biomedix (formerly Avicenna Medica; now a subsidiary of the Xenova group) and Nycomed, together with Japanese licensee Sosei and Chinese licensee PharmaEngine, are developing TransMID, a transferrin-mediated diphtheria toxin delivery system for the potential treatment of adult, recurrent, inoperable, high-grade glioma (as TransMID-107R). It is also under investigation for other forms of brain cancer, including early brain cancer (as TransMID-107N), metastatic brain cancer (as TransMID-107M) and pediatric brain cancer (as TransMID-107P). TransMID is currently undergoing phase III clinical trials.